Loading...
Bienvenue sur la collection HAL du laboratoire de BECCOH
Quelques conseils pour une publication "idéHALe"
• Pensez à respecter la signature institutionnelle
Université Paris-Saclay, UVSQ, BECCOH, 92104, Boulogne-Billancourt, France..
• Participez à l'accès ouvert
N'attendez pas : dès que votre article est en ligne, déposez dans Hal sa version acceptée pour publication et indiquez un embargo de 6 mois.
La loi pour une république numérique vous autorise en effet à partager cette version 6 mois après publications, quelque-soit l'éditeur
Plus d'informations Archives Ouverte : quid de mes droits d'auteurs ?
• Vous souhaitez disposer d'une page web référençant toutes vos publications ?
Créez vous en 5 minutes un idHal et un CVHAL
N'hésitez pas à nous contacter pour toutes questions,
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
nous serions ravis d'échanger avec vous hal.bib@uvsq.fr
Dernières Publications en accès ouvert dans Hal
-
Paul Takam Kamga, Marie Mayenga, Louise Sebane, Adrien Costantini, Catherine Julie, et al.. Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2024, 188, pp.107447. ⟨10.1016/j.lungcan.2023.107447⟩. ⟨hal-04517531⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. European Journal of Cancer, 2023, 193, pp.113252. ⟨10.1016/j.ejca.2023.113252⟩. ⟨inserm-04209605⟩
-
Alexander Stratigos, Claus Garbe, Clio Dessinioti, Celeste Lebbe, Alexander van Akkooi, et al.. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention–Update 2023. European Journal of Cancer, 2023, 193, pp.113251. ⟨10.1016/j.ejca.2023.113251⟩. ⟨inserm-04210036⟩
-
Julien Taïeb, Olivier Bouche, Thierry André, Karine Le Malicot, Pierre Laurent-Puig, et al.. Avelumab vs Standard Second-Line Chemotherapy in Patients with Metastatic Colorectal Cancer and Microsatellite Instability: A Randomized Clinical Trial. JAMA oncology, 2023, 9 (10), ⟨10.1001/jamaoncol.2023.2761⟩. ⟨hal-04322943⟩
-
Amandine Desette, Pierre-Olivier Guichet, Sheik Emambux, Konstantin Masliantsev, Ulrich Cortes, et al.. Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features. Cellular and Molecular Gastroenterology and Hepatology, 2023, 16 (5), pp.757-782. ⟨10.1016/j.jcmgh.2023.07.008⟩. ⟨hal-04302791⟩
Mots clés
Systemic therapy
AML
Beta-catenin
Polyomavirus
Biomarkers
Cancer bronchique non à petites cellules
Melanoma
Circulating cell-free DNA
Children
Lung adenocarcinoma
Langerhans cell histiocytosis
Cemiplimab
Resistance
Abdominal pain
Biomarker
Anti-Tumor pharmacology
Mesenchymal stromal cells
BRAFV600E
ADN tumoral circulant
Prevention
C797S
BRAFV600-mutant melanoma
Advanced melanoma
Follow-up
Merkel cell carcinoma
EGFR
ALK
Colorectal carcinoma
Androgen insensitivity
Surgical excision
Nivolumab
Locally advanced
Allelic imbalance
Bariatric surgery
Dabrafenib
Sonic Hedgehog
Anti-CTLA-4
Advanced
Body mass index
Adapted physical activity molecular diagnosis oligometastatic disease pancreatic adenocarcinoma KRAS mutation
BRAFV600E mutation
Adjuvant
Prognosis
Immunomodulation
ACTH
Bone marrow niche
Molecular targeted therapies
Adjuvant FOLFOX
Immunotherapy
2-chlorodeoxyadenosine
Metastatic
BRAF V600-mutation
Trametinib
Wnt
Radiotherapy
Plasma
Osimertinib
Chemotherapy
Colon cancer
Radiofrequency ablation
TNM classification
ALK rearrangement
Treatment
Anti-PD1
Antineoplastic agents
Diagnosis
Crizotinib
Metastatic cSCC
Anti-PD1 blockade
Biliopancreatic diversion
Immune checkpoint inhibitor
Chemoresistance
Adverse events
Antibody-drug conjugate
Anti-CTLA-4 anti-PD-1 elderly immune checkpoint inhibitors melanoma nonagenarian octogenarian
Histiocytosis
Adjuvant therapy
Safety
Staging
BRAF V600E
Circulating tumor DNA
Cutaneous squamous cell carcinoma
Brain Metastases
Colorectal cancer
Acute generalized exanthematous pustulosis
Abscopal effect
Abscopal effect anti-PD-1 antibody melanoma nivolumab pembrolizumab radiotherapy
Targeted therapy
Anti-PD-1
Immunohistochemistry
AZD9291
BRAF
Non-small cell lung cancer
Survival
Invasive cutaneous squamous cell carcinoma
Gastric bypass
CARMN
Prognostic
Anti-PD-1 antibody
Cancer